Compare Bank of New York Mellon Corp (BNY) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of New York Mellon Corp vs Crispr Therapeutics AG — how do they compare? Bank of New York Mellon Corp trades at $163.99 (market cap $110.55B), while Crispr Therapeutics AG trades at $54.15 (market cap $5.22B). The key difference: Bank of New York Mellon Corp is far larger — about 21.2× Crispr Therapeutics AG's market cap, and Bank of New York Mellon Corp pays a 1.36% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| BNY | CRSP | |
|---|---|---|
Market Cap | $110.55B | $5.22B |
Sector | Financials | Health |
52-Week High | $162.93 | $76.78 |
52-Week Low | $101.00 | $44.34 |
Dividend Yield | 1.36% | — |
Enterprise Value | — | $3.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNY trades at $162.25, up 1.2% with a bullish technical outlook. The company shows strong fundamentals with consistent earnings beats, revenue growth from $18.3B in 2024 to $19.8B in 2025, and a robust 29.96% net income margin. Recent developments include board expansion and digital transfer agency capabilities. Analyst consensus is positive with a $170.36 price target and no sell ratings.
BNY presents a favorable investment case with strong profitability and growth trajectory. Key opportunities include expanding digital services and market share gains. Risks involve high investing cash outflows and interest expense of $20.68B. The stock offers upside to consensus target with solid institutional support.
CRISPR Therapeutics (CRSP) trades at $53.99, down 0.15% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by 151% YoY growth in CASGEVY sales to $76 million. Financials show deep losses with a net income margin of -4,101.26% in 2025, though cash flow improved to a net positive $49.30M. Recent news highlights strong analyst optimism and pipeline advancements.
Outlook remains speculative with high growth potential from gene-editing therapies like CASGEVY, but significant risks persist from ongoing losses and clinical trial outcomes. Wall Street consensus is bullish with a $82.67 price target, implying 53% upside, though investors face volatility from earnings misses and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of New York Mellon Corp
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
